Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.
作者信息
Wang Changsong, Kang Kai, Gao Yan, Ye Ming, Lan Xiuwen, Li Xueting, Zhao Mingyan, Yu Kaijiang
机构信息
The First Affiliated Hospital of Harbin Medical University and Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China (C.W.).
The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (K.K., M.Z., K.Y.).
出版信息
Ann Intern Med. 2020 Sep 15;173(6):499-501. doi: 10.7326/L20-0354. Epub 2020 May 12.
Abstract
摘要
相似文献
1
Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.新型冠状病毒肺炎合并急性呼吸窘迫综合征患者体液中的细胞因子水平：病例报告
Ann Intern Med. 2020 Sep 15;173(6):499-501. doi: 10.7326/L20-0354. Epub 2020 May 12.
2
2019 Novel Coronavirus Pandemic: What Do We Know?2019新型冠状病毒大流行：我们了解什么？
S D Med. 2020 Jun;73(6):262-264.
3
Cardiovascular phenotypes in ventilated patients with COVID-19 acute respiratory distress syndrome.患有新型冠状病毒肺炎急性呼吸窘迫综合征的通气患者的心血管表型
Crit Care. 2020 May 18;24(1):236. doi: 10.1186/s13054-020-02958-8.
4
Blood and blood product use during COVID-19 infection.新型冠状病毒肺炎感染期间的血液及血液制品使用情况。
Am J Hematol. 2020 Jul;95(7):E158-E160. doi: 10.1002/ajh.25823. Epub 2020 Apr 22.
5
Helmet continuous positive airway pressure and prone positioning: A proposal for an early management of COVID-19 patients.头盔式持续气道正压通气与俯卧位通气：关于COVID-19患者早期管理的一项建议
Pulmonology. 2020 Jul-Aug;26(4):186-191. doi: 10.1016/j.pulmoe.2020.04.014. Epub 2020 Apr 30.
6
COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.与细菌性脓毒症休克患者相比，新冠病毒疾病（COVID-19）患者的免疫抑制表现不那么明显。
Crit Care. 2020 May 26;24(1):263. doi: 10.1186/s13054-020-02896-5.
7
Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema: Therapeutic Implications.鉴别新型冠状病毒肺炎与急性呼吸窘迫综合征和高原肺水肿：治疗意义
Circulation. 2020 Jul 14;142(2):101-104. doi: 10.1161/CIRCULATIONAHA.120.047915. Epub 2020 May 5.
8
[Fatal outcome of coronavirus disease 2019 in a previously healthy 50-year-old man].[一名既往健康的50岁男性2019冠状病毒病的致命结局]
Ugeskr Laeger. 2020 Apr 13;182(16).
9
Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者急性呼吸窘迫综合征期间的炎症反应细胞
Ann Intern Med. 2020 Sep 1;173(5):402-404. doi: 10.7326/L20-0227. Epub 2020 Apr 13.
10
Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock.新冠肺炎、ARDS 和感染性休克患者对血管紧张素 II 的血压敏感性意外增加。
Chest. 2020 Aug;158(2):e55-e58. doi: 10.1016/j.chest.2020.04.015. Epub 2020 Apr 23.
引用本文的文献
1
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.中国奥密克戎流行期间，重症和危重症奥密克戎感染患者的免疫和炎症特征。
BMC Infect Dis. 2024 Aug 9;24(1):809. doi: 10.1186/s12879-024-09652-y.
2
Comparative analysis of CRP as a biomarker of the inflammatory response intensity among common viral infections affecting the lungs: COVID-19 versus influenza A, influenza B and respiratory syncytial virus.比较分析 CRP 作为常见肺部病毒感染的炎症反应强度的生物标志物：COVID-19 与甲型流感、乙型流感和呼吸道合胞病毒。
Clin Exp Med. 2023 Dec;23(8):5307-5313. doi: 10.1007/s10238-023-01176-0. Epub 2023 Aug 28.
3
Pharmacologic Treatment and Management of Coronavirus Disease 2019.新型冠状病毒疾病 2019 的药物治疗和管理。
Infect Dis Clin North Am. 2022 Jun;36(2):349-364. doi: 10.1016/j.idc.2022.02.001. Epub 2022 Feb 10.
4
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.转录组分析揭示了用于SARS-CoV-2特异性T细胞治疗产品的最佳细胞因子组合。
Mol Ther Methods Clin Dev. 2022 Jun 9;25:439-447. doi: 10.1016/j.omtm.2022.04.013. Epub 2022 Apr 29.
5
Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.沙特阿拉伯利雅得重症监护病房 COVID-19 患者使用法维拉韦的临床转归和治疗效果概述。
J Infect Public Health. 2022 Apr;15(4):389-394. doi: 10.1016/j.jiph.2022.01.013. Epub 2022 Feb 15.
6
Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury.直接比较不同治疗细胞类型对与 COVID-19 急性肺损伤相关的炎症细胞因子的敏感性。
Stem Cell Res Ther. 2022 Jan 15;13(1):20. doi: 10.1186/s13287-021-02699-7.
7
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.巴瑞替尼成功治疗一名因抗CD20单克隆抗体治疗导致严重B细胞发育不全的新冠长期感染者：病例报告
Respir Med Case Rep. 2021;34:101560. doi: 10.1016/j.rmcr.2021.101560. Epub 2021 Nov 29.
8
Cytokine levels in sputum, not serum, may be more helpful for indicating the damage in the lung and the prognosis of severe COVID-19 - A case series.痰而非血清中的细胞因子水平可能更有助于指示严重 COVID-19 肺部损伤和预后——一项病例系列研究。
J Infect. 2021 Nov;83(5):e6-e9. doi: 10.1016/j.jinf.2021.08.026. Epub 2021 Aug 19.
9
New-onset status epilepticus in SARS-CoV-2 infection: a case series.新型冠状病毒2型感染中的新发癫痫持续状态：病例系列
Neurol Sci. 2022 Mar;43(3):2015-2020. doi: 10.1007/s10072-021-05536-0. Epub 2021 Aug 16.
10
Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D.COVID-19 的肺中心性炎症：维生素 D 的潜在调节作用。
Nutrients. 2021 Jun 28;13(7):2216. doi: 10.3390/nu13072216.
本文引用的文献
1
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
2
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
Toxicity management for patients receiving novel T-cell engaging therapies.接受新型T细胞衔接疗法患者的毒性管理
Curr Opin Pediatr. 2014 Feb;26(1):43-9. doi: 10.1097/MOP.0000000000000043.
Zotero 插件